Elsevier

Life Sciences

Volume 78, Issue 22, 25 April 2006, Pages 2543-2549
Life Sciences

COX-2 mediates morphine-induced delayed cardioprotection via an iNOS-dependent mechanism

https://doi.org/10.1016/j.lfs.2005.10.032Get rights and content

Abstract

Cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) have been shown to be mediators of cardioprotection induced by ischemic preconditioning and opioids. However, it is not known whether COX-2 is involved in morphine-induced cardioprotection accompanied with iNOS. Therefore, we investigated the role of COX-2 in morphine-induced cardioprotection and the effect of iNOS on COX-2. Myocardial ischemia was induced by a 45-min coronary artery occlusion in mice. Infarct size (IS) as a percentage of the area at risk (AAR) was determined by triphenyltetrazolium chloride staining. The COX-2-selective inhibitor NS-398 was used to investigate the role of COX-2. Expression of COX-2 was assessed by Western blotting, and the myocardial prostaglandin (PG)E2 and 6-keto-PGF contents were measured using enzyme immunoassays. The iNOS-selective inhibitor SMT and iNOS gene-knockout mice were used to investigate the effect of iNOS on COX-2. IS/AAR was reduced significantly 1 and 24 h after morphine preconditioning. The infarct-sparing effect 24 h after morphine administration, but not the cardioprotection 1 h later, was completely abolished by NS-398. Marked enhancement of myocardial COX-2 expression was measured 24 h after morphine preconditioning associated with up-regulation of myocardial contents of PGE2 and 6-keto-PGF. Neither the level of COX-2 nor the contents of PGE2 and 6-keto-PGF were enhanced 1 h later. Administration of SMT and targeted abrogation of iNOS gene blocked the enhancement of myocardial PGE2 and 6-keto-PGF 24 h after morphine administration but did not inhibit the up-regulation of COX-2 expression. We concluded that COX-2 mediates morphine-induced delayed cardioprotection via an iNOS-dependent pathway.

Introduction

Exposure of the heart to a sublethal ischemic stress renders the myocardium relatively resistant to a subsequent ischemic insult, which is known as ischemic preconditioning. As a potent endogenous form of cardioprotection against ischemia–reperfusion injury, ischemic preconditioning has been described to be a biphasic event: the acute phase is limited to 1–3 h after a brief ischemic stimulus, and the delayed phase emerges 24 h later and may last up to 72 h (Murry et al., 1986, Tang et al., 1996). Opioids have been shown to confer both the acute and the delayed phase of cardioprotection similar to ischemic preconditioning (Schultz et al., 1996, Patel et al., 2003). As one of the most widely used opioids for the treatment of pain, morphine has been shown to induce acute cardioprotection in cardiac myocytes (McPherson and Yao, 2001), isolated working hearts (Shi et al., 2003) and in vivo models (Schultz et al., 1996, Ludwig et al., 2003). We have previously reported that morphine also produces delayed cardioprotection in mice 24 h after administration (Jiang et al., 2004).

Cardioprotection induced by preconditioning is a complex process that involves a network of intricate regulatory mechanisms at the levels of cell signaling and gene expression. Pharmacological and genetic evidence has convincingly shown that the inducible nitric oxide synthase (iNOS) plays a necessary role in mediating the cardioprotective effects conferred by ischemic preconditioning. In our previous work, we have also demonstrated an essential role for iNOS in mediating morphine-induced delayed cardioprotection (Jiang et al., 2004). Besides iNOS, recent evidence indicates that cardioprotection induced by ischemic preconditioning and δ-opioid receptor agonists is mediated by cyclooxygenase-2 (COX-2) and that COX-2-dependent synthesis of prostanoids is necessary for the observed cardioprotective effects (Shinmura et al., 2000, Shinmura et al., 2002a, Shinmura et al., 2002b, Kodani et al., 2002). Since both iNOS and COX-2 are obligatory mediators of ischemic preconditioning, the questions arise as to whether COX-2 is also involved in mediating the cardioprotection induced by morphine and whether there is an interaction between iNOS and COX-2 or they act as independent effectors of morphine-induced cardioprotection.

Therefore the current study was designed to define the function of COX-2 in morphine-induced biphasic cardioprotection in a murine model of coronary artery occlusion in vivo and to investigate the effect of iNOS on COX-2 in mediating the cardioprotection using an iNOS-selective inhibitor and iNOS gene-knockout mice.

Section snippets

Animals

Adult male wild type (WT) mice (B6129PF2/J) and iNOS gene-knockout (/) mice (B6, 129) (Jackson Laboratory, Bar Harbor, ME) weighing 25 to 30 g were used in this study (Guo et al., 1999). The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of Hamamatsu University School of Medicine and in accordance with the NIH Guide for the Care and Use of Laboratory Animals.

Drugs and chemicals

Morphine was purchased from Shionogi Co. (Osaka, Japan). NS-398, S-methylthiourea sulfate

Results

A total of 45 mice were initially included in the protocol for the infarct-size study. Five mice were excluded because of a marked hypotension (MAP < 30 mm Hg) during coronary occlusion and reperfusion. Another two mice were omitted as a result of technical difficulties with the experimental preparation. Complete data were obtained in the remaining 38 mice. Final numbers in the groups are as follows: Control n = 6; M 1 h, n = 6; M 24 h, n = 7; NS, n = 6; M 1 h + NS, n = 6; M 24 h + NS, n = 7.

Discussion

The salient findings of the current study can be summarized as follows: (1) morphine induces biphasic cardioprotection in mice. Only the delayed cardioprotection, but not the acute phase, is associated with the up-regulation of myocardial content of PGs and expression of COX-2, and is abolished by selective inhibition of COX-2. (2) Selective inhibition of iNOS or targeted abrogation of iNOS gene blocks the enhancement of myocardial PGs but does not inhibit the up-regulation of COX-2 expression.

Conclusion

In conclusion, the current study demonstrates that the delayed cardioprotection induced by morphine, but not the acute phase, is mediated by COX-2 via an iNOS-dependent pathway. To the best of our knowledge, this is the first study which provides a direct link between COX-2 pathway and iNOS pathway in mediating morphine-induced delayed cardioprotection.

References (36)

  • H.H. Patel et al.

    COX-2 and iNOS in opioid-induced delayed cardioprotection in the intact rat

    Life Sciences

    (2004)
  • W.L. Smith et al.

    Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2

    Journal of Biological Chemistry

    (1996)
  • Y.T. Xuan et al.

    Mechanism of cyclooxygenase-2 upregulation in late preconditioning

    Journal of Molecular and Cellular Cardiology

    (2003)
  • C. Arnaud et al.

    Role of nitric oxide synthases in the infarct size-reducing effect conferred by heat stress in isolated rat hearts

    British Journal of Pharmacology

    (2001)
  • R. Bolli et al.

    The protective effect of late preconditioning against myocardial stunning in conscious rabbits is mediated by nitric oxide synthase. Evidence that nitric oxide acts both as a trigger and as a mediator of the late phase of ischemic preconditioning

    Circulation Research

    (1997)
  • H. Darius et al.

    Cardiovascular actions in vitro and cardioprotective effects in vivo of nileprost, a mixed type PGI2/PGE2 agonist

    Journal of Cardiovascular Pharmacology

    (1987)
  • S.T. Davidge et al.

    Nitric oxide produced by endothelial cells increases production of eicosanoids through activation of prostaglandin H synthase

    Circulation Research

    (1995)
  • B. Dawn et al.

    IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2

    Cardiovascular Research

    (2004)
  • D.C. Goodwin et al.

    Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis

    FASEB Journal

    (1999)
  • Y. Guo et al.

    The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene

    Proceedings of the National Academy of Sciences of the United States of America

    (1999)
  • X. Jiang et al.

    Inducible nitric oxide synthase mediates delayed cardioprotection induced by morphine in vivo: evidence from pharmacologic inhibition and gene-knockout mice

    Anesthesiology

    (2004)
  • E. Kodani et al.

    Delta-opioid receptor-induced late preconditioning is mediated by cyclooxygenase-2 in conscious rabbits

    American Journal of Physiology. Heart and Circulatory Physiology

    (2002)
  • Q. Li et al.

    Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism

    Circulation Research

    (2003)
  • L.M. Ludwig et al.

    Morphine enhances pharmacological preconditioning by isoflurane: role of mitochondrial K(ATP) channels and opioid receptors

    Anesthesiology

    (2003)
  • N. Maulik et al.

    Nitric oxide signaling in ischemic heart

    Cardiovascular Research

    (1995)
  • B.C. McPherson et al.

    Morphine mimics preconditioning via free radical signals and mitochondrial K(ATP) channels in myocytes

    Circulation

    (2001)
  • C.E. Murry et al.

    Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium

    Circulation

    (1986)
  • H.H. Patel et al.

    12-lipoxygenase in opioid-induced delayed cardioprotection: gene array, mass spectrometric, and pharmacological analyses

    Circulation Research

    (2003)
  • Cited by (32)

    • Anti-inflammatory effects of diethylcarbamazine: A review

      2014, European Journal of Pharmacology
    • Antiarrhythmic effect of prolonged morphine exposure is accompanied by altered myocardial adenylyl cyclase signaling in rats

      2012, Pharmacological Reports
      Citation Excerpt :

      This also conforms well to the results of some earlier investigations conducted on other models. It is well known that morphine can mediate acute or delayed preconditioning-like effects [19, 48]. Moreover, Peart and co-workers [41] have recently described a profound cardioprotective pheno-type in mice that was afforded by prolonged continuous exposure to morphine (75-mg subcutaneous pellet; 5 days).

    • Deterioration of myocardial injury due to dexmedetomidine administration after myocardial ischaemia

      2010, Resuscitation
      Citation Excerpt :

      In our previous ischaemia-reperfusion study, we reported that dexmedetomidine has a cardioprotective effect when it is administered before ischaemia.1 Anaesthetics such as morphine and volatile anaesthetics reportedly have a cardioprotective effect when they are administered before2–4 and after ischaemia.5,6 Dexmedetomidine may be useful for sedation after cardiac surgeries if it could be proven that it has a cardioprotective effect when administered after ischaemia.

    • Nitric oxide and renal protection in morphine-dependent rats

      2010, Free Radical Biology and Medicine
      Citation Excerpt :

      Although 5 days of treatment with morphine increased iNOS expression and NO production, L-NAME administration before IR inhibited iNOS activity and probably other NOS isoforms, which attenuated NO production, leading to the presence of higher iNOS in renal tissue without increased NO production (Figs. 5B and 6). Previous studies have shown that morphine increases NO release [22] and activates NOS subtypes including iNOS, leading to myocardial tissue protection in the late phase after 24 h of preconditioning [51,52]. The role of iNOS activation and NO release in delayed renal protection against IR injury has also been demonstrated [17,35,53].

    View all citing articles on Scopus

    Xiaojing Jiang and Enyi Shi contributed equally to this work. Dr. Shi is supported by Japan Society for the Promotion of Science. Xiaojing Jiang and Enyi Shi are currently affiliated with China Medical University.

    View full text